Protein identified as a potential biomarker and therapeutic target for aggressive neuroendocrine carcinomas

Mt. Sinai researchers identify six-gene pattern to predict drug success in myeloma

Researchers at the Icahn School of Medicine at Mount Sinai have discovered how genetics can affect the success of venetoclax, a treatment for multiple myeloma. Their study was published this month in the journal Blood Neoplasia.

December 06, 2024

Vol.50 No.45

Drugs & Targets

FDA grants accelerated approval to zenocutuzumab-zbco for NSCLC and pancreatic adenocarcinoma

FDA has granted accelerated approval to zenocutuzumab-zbco (Bizengri) for adults

December 06, 2024

Vol.50 No.45

Drugs & Targets

Merus and Partner Therapeutics announce license agreement for the U.S. commercialization of zenocutuzumab in NRG1 fusion-positive cancer

Merus a clinical-stage oncology company developing innovative, full-length multispecific antibodies and Partner Therapeutics Inc., a private, fully-integrated biotechnology company with a focus in hematology and oncology, announced they have entered into an agreement in which Merus has exclusively licensed to PTx the right to commercialize zenocutuzumab (Zeno, also called Bizengri) for the treatment of NRG1 fusion-positive cancer in the U.S.

December 06, 2024

Vol.50 No.45

Clinical Roundup

Tracing cancer back to birth uncovers promising biomarkers for prevention, early detection, targeted treatment of childhood leukemia

Molecular markers in blood at birth are linked to later development of acute lymphoblastic leukemia, the most common cancer type that affects children, according to a study published in Molecular Cancer.

October 25, 2024

Vol.50 No.40

Drugs & Targets

Daiichi Sankyo, Merck collaborate to develop and commercialize MK-6070, an investigational delta-like ligand 3 targeting T-cell engager

Daiichi Sankyo and Merck have expanded their existing global co-development and co-commercialization agreement for three investigational DXd antibody-drug conjugates to include Merck’s MK-6070, an investigational delta-like ligand 3 targeting T-cell engager.

August 09, 2024

Vol.50 No.32

Clinical Roundup

ACCC and LUNGevity launch virtual roadmap to support EHR integration for biomarker testing

The Association of Cancer Care Centers and LUNGevity have launched the Electronic Health Records Integrations for Biomarker Testing: Roadmap, a new virtual resource to support multidisciplinary cancer care teams prepare, implement, and evaluate electronic health record integrations for biomarker testing.

May 31, 2024

Vol.50 No.22

Protein identified as a potential biomarker and therapeutic target for aggressive neuroendocrine carcinomas

YOU MAY BE INTERESTED IN

Mt. Sinai researchers identify six-gene pattern to predict drug success in myeloma

FDA grants accelerated approval to zenocutuzumab-zbco for NSCLC and pancreatic adenocarcinoma

Merus and Partner Therapeutics announce license agreement for the U.S. commercialization of zenocutuzumab in NRG1 fusion-positive cancer

Tracing cancer back to birth uncovers promising biomarkers for prevention, early detection, targeted treatment of childhood leukemia

Daiichi Sankyo, Merck collaborate to develop and commercialize MK-6070, an investigational delta-like ligand 3 targeting T-cell engager

ACCC and LUNGevity launch virtual roadmap to support EHR integration for biomarker testing

Renew today!

Subscriber content

Never miss an issue!

Login